A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-06-30

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is:

1. to find out the structural or functional effects of selective serotonin reuptake inhibitors (SSRI) in major depressive disorder (MDD);
2. find special abnormalities in depression secondary to other disease, e.g., autoimmune disease like systemic lupus erythematosus (SLE).
3. find the relationship between the efficacy of antidepressant and the change of neuroimaging in MDD
4. to find possible predispose to MDD
5. to explore the DNA methylation status in depression;

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram

NCT00707863

Major Depression

COMPLETED PHASE4

Neural, Genetic, and Peripheral Correlates of SSRI Pharmaco-Response

NCT01251471

Depression

COMPLETED PHASE4

Functional Neuroimaging in Depression

NCT00343070

Major Depression

COMPLETED PHASE2

Serotonin Transporter Genetic Variation and Amygdalar Activation Correlates of Antidepressant Response

NCT00456430

Depression

COMPLETED PHASE4

Pattern Separation in Major Depressive Disorder

NCT07139834

Major Depressive Disorder (MDD)

NOT_YET_RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. to explore the pathology of depression
2. to identify the difference between MDD and depression secondary to other disease ,especially autoimmune disease
3. to explore the effect of gene-environment interaction on the epigenetic regulation of the depression

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression Depression Secondary to Other Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A,1

A: Escitalopram, 20 mg/day,8weeks

Group Type EXPERIMENTAL

Escitalopram

Intervention Type DRUG

A,1: Escitalopram, oral, 20 mg/day, 8 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Escitalopram

A,1: Escitalopram, oral, 20 mg/day, 8 weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* DSM-IV Major Depression or Dysthymia
* Age 18-65
* Physically healthy
* Drug-free

Exclusion Criteria

* Body metal (e.g., wire stitches, screws in bones, stainless steel hips)
* History of Psychosis or Epilepsy
* Current (past six months) Substance Use Disorder (illicit drugs and/or alcohol)
* Bipolar I
* Need for wash-out from effective treatment in order to participate
* Pregnant
* High suicide risk
* Currently taking (within 2 weeks; 4 weeks for Fluoxetine) antidepressants

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes